CF PHARMTECH (02652) News

CF PharmTech Announces 2025 Extraordinary General Meeting

TipRanksNov 26 18:39

CF PharmTech Launches H-Share Full Circulation Plan; Shares Slip 2%

MT NewswiresNov 26 10:55

Changfeng Pharmaceutical (02652): Proposal for the Implementation of Full H-share Convertibility

Changfeng Pharmaceutical (02652) announced that on November 25, 2025, the company's board of directors considered and approved the construction...

Zhitong FinanceNov 25 18:15

This Week's Bull Stocks in the Hong Kong Market | Guofu Quantum reported positive earnings, surging nearly 10% this week; Chongshu Energy rose over 6%, with a cumulative gain of nearly 40% over two weeks after receiving approval from the China Securities

CSSC Defense Security gained over 6% this week as the shipbuilding industry shows upward momentum, with institutions optimistic about increased attention on the military sector.

Futu NewsNov 22 11:22

The board of Changfeng Pharmaceutical (02652.HK) has approved a resolution authorizing the repurchase of H shares.

Gelonghui, November 13th丨Changfeng Pharmaceuticals (02652.HK) announced that the board has reviewed and approved a resolution concerning a proposed general mandate to be granted to the directors for repurchasing the company’s issued H-shares listed on the Main Board of the Stock Exchange of Hong Kong (“Share Repurchase Mandate”). This proposal will be submitted to the company’s shareholders for consideration and approval at an extraordinary general meeting to be convened at an appropriate time.

Gelonghui FinanceNov 13 07:09

Changfeng Pharmaceuticals (02652.HK): Proposal to Adopt H-share Incentive Plan

Gelonghui, November 13th丨Changfeng Pharmaceuticals (02652.HK) announced that on November 12, 2025, it had resolved to propose the adoption of the company's 2025 H-share Incentive Trust Plan (“H-share Incentive Plan”). The H-share Incentive Plan aims to align the interests of the company’s employees, management, and shareholders, attract, retain, and motivate key talents, reward their contributions, and drive the company's sustainable development and long-term success.

Gelonghui FinanceNov 13 07:05

Zhitong Finance HK Stock November Investment Strategy and Top 10 Gold Stocks

Following the adjustment in October, opportunities in November are likely to increase, as a decline serves as the best litmus test, helping us identify which assets have stood the test of scrutiny. Therefore, the strategy need not be overly complex; regardless of market volatility, simply put: focus on resilient asset classes.

Zhitong FinanceNov 2 19:20

HKG Market Moves | Changfeng Pharmaceuticals (02652) rose nearly 3% before noon as the company completed the first patient enrollment for its minimally invasive interventional device in the treatment of emphysema.

Changfeng Pharmaceuticals (02652) rose nearly 3% in the morning session. As of the time of writing, it was up 2.74%, trading at HKD 29.2, with a turnover of HKD 5.3645 million.

Zhitong FinanceOct 17 11:49

Hong Kong IPO Weekly | Energy drink giant Eastroc Beverage resubmits listing application; three new stocks double in value

①Functional beverage giant Eastroc Beverage has filed again. What are the highlights? ②All three newly listed stocks doubled in value. Why is the market so enthusiastic?

cls.cnOct 12 15:56

Hong Kong Stocks Close | Three Major Indices Post Weekly Declines; IPO Performance Draws Attention

① What are the reasons for the adjustment in gold stocks today? ② What caused the significant drop in CATL?

cls.cnOct 10 16:40

Hong Kong Stocks End Lower Amid AI Bubble Fear; CF PharmTech Debuts In Hong Kong

MT NewswiresOct 8 16:50

Hong Kong Stocks Close (10.08) | Hang Seng Index Down 0.48%, Gold Stocks Continue to Surge, New Stock Changfeng Pharmaceutical (02652) Ends Up 161%

Hong Kong's three major indices opened lower and quickly plummeted, with the Hang Seng Index once falling by more than 1.6%. The losses gradually narrowed throughout the day thereafter.

Zhitong FinanceOct 8 16:45

Changfeng Pharmaceuticals surged over 160% on its debut! The entire sector is taking off, with the pharmaceutical newcomer Xuanzhu Biologics-B closing subscription on the 10th.

This year, newly listed pharmaceutical stocks have delivered exceptional returns, with over 80% closing higher on their debut. The top five performers all surged by more than 100% on their first day. Today's listing of Changfeng Pharmaceuticals yielded the highest return, with a gain of nearly HKD 12,000 per lot.

Securities Daily ChinaOct 8 16:27

Hong Kong Stocks Midday Review | Hang Seng Index fell 1.07% in the morning session, with gold stocks extending recent gains.

Gold stocks extended their recent rally, with New York futures gold prices breaking through the $4,000 mark.

Zhitong FinanceOct 8 12:00

The decline in Hong Kong stocks once widened to over 400 points, with Longfor Properties plunging 7%. Some gold mining stocks hit record highs against the market trend, while Changfeng (02652.HK) surged nearly threefold on its debut.

The ongoing U.S. government shutdown has driven investors to seek safe-haven assets, with gold futures prices surging past $4,000 per ounce for the first time on Tuesday (7th), repeatedly hitting new highs. As China's National Day Golden Week comes to an end, the Shanghai and Shenzhen stock markets are set to resume trading tomorrow (9th). Following a pause in "northbound funds," Hong Kong stocks resumed trading this morning (8th) after the holiday, opening 57 points lower. The decline widened significantly during early trading, falling as much as 440 points to reach a low of 26,517 before narrowing slightly. The latest reading stands at 26,675, down 282 points or approximately 1%, with turnover reaching 66.257 billion yuan. Real estate stocks remain weak; Longfor (00960.HK) opened 8.4% lower with a gap, hitting a low of 9.9 yuan, and is currently trading at 10.0 yuan.

AASTOCKSOct 8 10:19

The decline in AI-related stocks weighed on Hong Kong's market, with the Hang Seng Tech Index falling by 2%. Gold stocks gained favor, while the A50 index dropped over 1%.

Technology stocks and artificial intelligence concept stocks led the decline. Baidu Group fell nearly 5%, SenseTime dropped nearly 4%, Alibaba declined by 3.7%, and SMIC also fell more than 3%. In addition, airline stocks and financial stocks also performed poorly, with China Southern Airlines falling nearly 4% and CICC dropping nearly 3%.

wallstreetcnOct 8 10:03

IPO First Day | CF Pharmicell, the producer of CF017, China’s best-selling inhaled drug, surged over 230% at its debut, with potential single-lot gains exceeding HKD 17,000.

Changfeng Pharmaceuticals primarily focuses on the research, development, production, and commercialization of inhalation technologies and inhaled drugs, with an emphasis on treating respiratory diseases. The company has developed a product portfolio that covers a wide range of patients, medical specialties, and therapeutic areas.

Futu NewsOct 8 09:49

Express News | Data Source Summary: Daily Highlights of Hong Kong Stock Market News (2025-10-08)

BreakingsOct 8 09:11

CF PharmTech Nets HK$525 Million From Hong Kong IPO Ahead of Trading Debut

MT NewswiresOct 8 07:12

HKEX IPO Update: Changfeng Pharmaceutical Debuts Today

Gelonghui, October 8th | Today, Changfeng Pharmaceuticals (2652.HK) was listed, and Xuanzhu Bio-B (2575.HK) launched its subscription.

Gelonghui FinanceOct 8 06:09